<p>Acumen Pharmaceuticals, Inc.（納斯達克代碼：ABOS - 獲取免費報告）首席財務官 Matt Zuga 於 1 月 8 日（星期四）出售了 6,888 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.82 美元出售，總交易額為 12,536.16 美元。出售後，首席財務官持有 209,951 股公司股票，價值 382,110.82 美元。此次交易使其持股減少了 3.18%。該出售在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。</p>
<p>獲取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>MarketBeat 週迴顧 – 7/17 - 7/21</li>
</ul>
<p>Matt Zuga 最近還進行了以下交易：</p>
<ul>
<li>1 月 7 日（星期三），Matt Zuga 出售了 5,805 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.99 美元出售，總交易額為 11,551.95 美元。</li>
<li>1 月 6 日（星期二），Matt Zuga 出售了 5,100 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.97 美元出售，總交易額為 10,047.00 美元。</li>
<li>1 月 5 日（星期一），Matt Zuga 出售了 4,000 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.96 美元出售，總價值為 7,840.00 美元。</li>
</ul>
<h2>Acumen Pharmaceuticals 股價下跌 5.0%</h2>
<p>在週一的交易中，ABOS 股價下跌 0.09 美元，跌至 1.72 美元。該股票交易量為 302,203 股，而其平均交易量為 269,914 股。該公司的債務與股本比率為 0.29，速動比率為 6.02，流動比率為 6.02。該公司的 50 日簡單移動平均為 1.94 美元，200 日簡單移動平均為 1.69 美元。該公司的市值為 1.0418 億美元，市盈率為-0.77，貝塔值為 0.23。Acumen Pharmaceuticals, Inc.的 1 年最低價為 0.86 美元，1 年最高價為 2.46 美元。</p>
<ul>
<li>Acumen 因阿爾茨海默病研究而飆升……市場預期其股價翻倍</li>
</ul>
<p>Acumen Pharmaceuticals（納斯達克代碼：ABOS - 獲取免費報告）最近在 11 月 12 日（星期三）發佈了季度財報。公司報告每股收益（EPS）為-0.44 美元，超出分析師一致預期的-0.63 美元，超出幅度為 0.19 美元。整體來看，股票分析師預計 Acumen Pharmaceuticals, Inc.在本年度將發佈-1.56 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>多位股票分析師最近對 ABOS 股票發佈了報告。Wall Street Zen 在 12 月 21 日（星期日）的研究報告中將 Acumen Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 14 日（星期二）的研究報告中重申了對 Acumen Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，美國銀行在 11 月 18 日（星期二）的報告中將 Acumen Pharmaceuticals 的目標股價從 9.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。四位研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，Acumen Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價格為 6.75 美元。</p>
<p><strong>閲讀我們關於 ABOS 的最新研究報告</strong></p>
<h2>Acumen Pharmaceuticals 的機構交易</h2>
<p>多家機構投資者最近對 ABOS 的持倉進行了調整。Y Intercept Hong Kong Ltd 在第二季度收購了 Acumen Pharmaceuticals 的新頭寸，價值約 291,000 美元。SG Americas Securities LLC 在第三季度收購了 Acumen Pharmaceuticals 的新股份，價值約 691,000 美元。Jacobs Levy Equity Management Inc.在第三季度購買了 Acumen Pharmaceuticals 的新股份，價值約 27,000 美元。Susquehanna International Group LLP 在第三季度將其在 Acumen Pharmaceuticals 的持倉提高了 26.5%。Susquehanna International Group LLP 目前持有 214,440 股公司股票，價值 367,000 美元，此前在上個季度又購買了 44,902 股。最後，美國銀行在第三季度將其在 Acumen Pharmaceuticals 的持倉提高了 45.4%。美國銀行目前持有 213,729 股公司股票，價值 365,000 美元，此前在上個季度又購買了 66,720 股。機構投資者和對沖基金持有公司 71.01% 的股票。</p>
<h2>關於 Acumen Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Acumen Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於針對神經退行性疾病的口服小分子療法的發現和開發。該公司利用一種集成了化學蛋白質組學、高通量篩選和計算化學的專有藥物發現平台，旨在識別和優化選擇性調節病理性蛋白質聚集的化合物。其方法旨在解決阿爾茨海默病、帕金森病、肌萎縮側索硬化症及相關蛋白病等疾病的基礎生物學問題。</p>
<p>該公司的產品管線包括多個處於不同臨牀前和早期臨牀開發階段的主要候選藥物。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票超過 Acumen Pharmaceuticals</li>
<li>崩盤前一個月</li>
<li>家族信託如何幫助保護您的財富</li>
<li>特朗普的手寫信將震驚他的反對者</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Acumen Pharmaceuticals 嗎？</h2>
<p>在您考慮 Acumen Pharmaceuticals 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Acumen Pharmaceuticals 並不在名單上。</p>
<p>雖然 Acumen Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ABOS

<p>Acumen Pharmaceuticals 首席財務官 Matt Zuga 以每股 1.82 美元的價格出售了 6,888 股，總計 12,536.16 美元，代表其持股減少了 3.18%。出售後，他持有 209,951 股，估值約為 382,110.82 美元。此交易已向美國證券交易委員會（SEC）披露。Zuga 本週早些時候還出售了其他股份。Acumen 的股票最近下跌了 5%，至 1.72 美元，市值為 1.0418 億美元，市盈率為 -0.77。分析師對該股票的評級不一，平均目標價格為 6.75 美元</p>

<p>Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $1.82, for a total transaction of $12,536.16. Following the sale, the chief financial officer owned 209,951 shares of the company's stock, valued at $382,110.82. The trade was a 3.18% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.（納斯達克代碼：ABOS - 獲取免費報告）首席財務官 Matt Zuga 於 1 月 8 日（星期四）出售了 6,888 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.82 美元出售，總交易額為 12,536.16 美元。出售後，首席財務官持有 209,951 股公司股票，價值 382,110.82 美元。此次交易使其持股減少了 3.18%。該出售在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。</p>
</div><p>Get <strong>Acumen Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 7/17 - 7/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 7/17 - 7/21</li>
</ul>
</div><p>Matt Zuga also recently made the following trade(s):</p>
<div class="lb-trans"><p>Matt Zuga 最近還進行了以下交易：</p>
</div><ul>
<li>On Wednesday, January 7th, Matt Zuga sold 5,805 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total transaction of $11,551.95.</li>
<li>On Tuesday, January 6th, Matt Zuga sold 5,100 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total transaction of $10,047.00.</li>
<li>On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.96, for a total value of $7,840.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>1 月 7 日（星期三），Matt Zuga 出售了 5,805 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.99 美元出售，總交易額為 11,551.95 美元。</li>
<li>1 月 6 日（星期二），Matt Zuga 出售了 5,100 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.97 美元出售，總交易額為 10,047.00 美元。</li>
<li>1 月 5 日（星期一），Matt Zuga 出售了 4,000 股 Acumen Pharmaceuticals 股票。股票以平均價格 1.96 美元出售，總價值為 7,840.00 美元。</li>
</ul>
</div><h2>Acumen Pharmaceuticals Trading Down 5.0%</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 股價下跌 5.0%</h2>
</div><p>ABOS traded down $0.09 during trading on Monday, hitting $1.72. 302,203 shares of the stock were exchanged, compared to its average volume of 269,914. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The firm has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $1.69. The firm has a market cap of $104.18 million, a price-to-earnings ratio of -0.77 and a beta of 0.23. Acumen Pharmaceuticals, Inc. has a 1 year low of $0.86 and a 1 year high of $2.46.</p>
<div class="lb-trans"><p>在週一的交易中，ABOS 股價下跌 0.09 美元，跌至 1.72 美元。該股票交易量為 302,203 股，而其平均交易量為 269,914 股。該公司的債務與股本比率為 0.29，速動比率為 6.02，流動比率為 6.02。該公司的 50 日簡單移動平均為 1.94 美元，200 日簡單移動平均為 1.69 美元。該公司的市值為 1.0418 億美元，市盈率為-0.77，貝塔值為 0.23。Acumen Pharmaceuticals, Inc.的 1 年最低價為 0.86 美元，1 年最高價為 2.46 美元。</p>
</div><ul>
<li>Acumen Soars on Alzheimer's Study...Street Sees It Doubling</li>
</ul>
<div class="lb-trans"><ul>
<li>Acumen 因阿爾茨海默病研究而飆升……市場預期其股價翻倍</li>
</ul>
</div><p>Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.19. As a group, equities analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals（納斯達克代碼：ABOS - 獲取免費報告）最近在 11 月 12 日（星期三）發佈了季度財報。公司報告每股收益（EPS）為-0.44 美元，超出分析師一致預期的-0.63 美元，超出幅度為 0.19 美元。整體來看，股票分析師預計 Acumen Pharmaceuticals, Inc.在本年度將發佈-1.56 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities analysts have recently issued reports on ABOS shares. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Acumen Pharmaceuticals in a research report on Tuesday, October 14th. Finally, Bank of America cut their price target on Acumen Pharmaceuticals from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, November 18th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Acumen Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $6.75.</p>
<div class="lb-trans"><p>多位股票分析師最近對 ABOS 股票發佈了報告。Wall Street Zen 在 12 月 21 日（星期日）的研究報告中將 Acumen Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 14 日（星期二）的研究報告中重申了對 Acumen Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，美國銀行在 11 月 18 日（星期二）的報告中將 Acumen Pharmaceuticals 的目標股價從 9.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。四位研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，Acumen Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價格為 6.75 美元。</p>
</div><p><strong>Read Our Latest Research Report on ABOS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ABOS 的最新研究報告</strong></p>
</div><h2>Institutional Trading of Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 的機構交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in ABOS. Y Intercept Hong Kong Ltd acquired a new position in Acumen Pharmaceuticals during the 2nd quarter valued at about $291,000. SG Americas Securities LLC acquired a new stake in Acumen Pharmaceuticals in the third quarter worth about $691,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Acumen Pharmaceuticals during the third quarter worth about $27,000. Susquehanna International Group LLP raised its position in shares of Acumen Pharmaceuticals by 26.5% in the 3rd quarter. Susquehanna International Group LLP now owns 214,440 shares of the company's stock valued at $367,000 after purchasing an additional 44,902 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Acumen Pharmaceuticals by 45.4% in the 3rd quarter. Bank of America Corp DE now owns 213,729 shares of the company's stock valued at $365,000 after purchasing an additional 66,720 shares during the last quarter. Institutional investors and hedge funds own 71.01% of the company's stock.</p>
<div class="lb-trans"><p>多家機構投資者最近對 ABOS 的持倉進行了調整。Y Intercept Hong Kong Ltd 在第二季度收購了 Acumen Pharmaceuticals 的新頭寸，價值約 291,000 美元。SG Americas Securities LLC 在第三季度收購了 Acumen Pharmaceuticals 的新股份，價值約 691,000 美元。Jacobs Levy Equity Management Inc.在第三季度購買了 Acumen Pharmaceuticals 的新股份，價值約 27,000 美元。Susquehanna International Group LLP 在第三季度將其在 Acumen Pharmaceuticals 的持倉提高了 26.5%。Susquehanna International Group LLP 目前持有 214,440 股公司股票，價值 367,000 美元，此前在上個季度又購買了 44,902 股。最後，美國銀行在第三季度將其在 Acumen Pharmaceuticals 的持倉提高了 45.4%。美國銀行目前持有 213,729 股公司股票，價值 365,000 美元，此前在上個季度又購買了 66,720 股。機構投資者和對沖基金持有公司 71.01% 的股票。</p>
</div><h2>About Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Acumen Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於針對神經退行性疾病的口服小分子療法的發現和開發。該公司利用一種集成了化學蛋白質組學、高通量篩選和計算化學的專有藥物發現平台，旨在識別和優化選擇性調節病理性蛋白質聚集的化合物。其方法旨在解決阿爾茨海默病、帕金森病、肌萎縮側索硬化症及相關蛋白病等疾病的基礎生物學問題。</p>
</div><p>The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同臨牀前和早期臨牀開發階段的主要候選藥物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Acumen Pharmaceuticals</li>
<li>A month before the crash</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Trump’s Hand-Written Letter Will Shock his Haters</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Acumen Pharmaceuticals</li>
<li>崩盤前一個月</li>
<li>家族信託如何幫助保護您的財富</li>
<li>特朗普的手寫信將震驚他的反對者</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABOS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acumen Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Acumen Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Acumen Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Acumen Pharmaceuticals 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Acumen Pharmaceuticals 並不在名單上。</p>
</div><p>While Acumen Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Acumen Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內部人士出售：Acumen Pharmaceuticals（納斯達克股票代碼：ABOS）的首席財務官出售了 6,888 股股票